MBX Biosciences, Inc. Common Stock

NASDAQ:MBX

Biotechnology

Healthcare
$53.42 -1.54%

-$0.64 today

Market cap
$2.65B
Beta
0.75
P/E (TTM)
-22.0
EPS (TTM)
-$1.86
52W Low $9.43High $45.85

Volume 0.73M

Average 0.65M

MBX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

MBX Biosciences, Inc. Common StockNASDAQ: MBX

Weighted Avg Shares · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares growth accelerates

Q3 FY2026 weighted avg shares of 48.56M shares rose 42.0% year over year, ahead of the +33.4% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 1.8% from the prior quarter. Over 3 fiscal years it compounded at +4.6% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +42.0% holds above the trailing-twelve-month pace of +33.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
48.56M+1.8% QoQ
Last fiscal yearDec 2025
36.51M+9.3% YoY
LTMSep 2026
44.83M+33.4% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+42.0%——
1 year+9.3%——
3-year CAGR+4.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
36.51M USD
Year-over-year change
+9.3%
3-year CAGR
+4.6%

Weighted Avg Shares vs competitors

How MBX compares with its peers on the latest reported figures

  • MBX's LTM Sep 2026 weighted avg shares of 44.83M shares is the 8th highest of the 9 companies compared; the peer median is 83.56M shares.
  • Its year-over-year change of +33.4% is the 3rd highest of 8, against a peer median of +7.8%.
  • Over three fiscal years its annual growth of +4.6% compares with a peer median of +7.6%.
MBX Competitors Peer median
Weighted Avg Shares for MBX and competitors
Company Period LTM YoY 3-year CAGR
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026167.52M +11.9%+5.8%
KLRAKailera Therapeutics, Inc.FY2025117.95M ——
VKTXViking Therapeutics, Inc.LTM Jun 2026114.45M +2.5%+13.6%
ALTAltimmune, Inc.LTM Mar 202698.99M +37.1%+23.4%
RYTMRhythm Pharmaceuticals, Inc.LTM Sep 202668.12M +7.8%+7.6%
ASNDAscendis Pharma A/SLTM Sep 202663.29M +4.9%+2.6%
BMEABiomea Fusion, Inc.LTM Mar 202656.46M +55.6%+21.3%
MBXMBX Biosciences, Inc. Common StockLTM Sep 202644.83M +33.4%+4.6%
ORMPOramed Pharmaceuticals Inc.LTM Mar 202641.42M +1.6%+2.0%
Peer median (excluding MBX) 83.56M+7.8%+7.6%

Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue000248K
Gross Profit000(248K)
Gross Margin————
Research & Development21.4M28.53M57.42M79.16M
Selling, General & Admin3.76M6.78M10.78M18.9M
Operating Expenses25.16M35.31M68.19M98.06M
Depreciation & Amortization56K157K244K248K
EBITDA(25.71M)(32.41M)(61.68M)(86.72M)
EBITDA Margin————
Operating Income(25.16M)(35.31M)(68.19M)(98.06M)
Operating Margin————
Interest Income372K2.75M6.27M11.08M
Interest Expense374K000
Other Income / Expenses(974K)2.75M6.27M11.08M
Income Before Tax(26.14M)(32.56M)(61.92M)(86.97M)
Pre-Tax Margin————
Income Tax Expense0000
Net Income(26.14M)(32.56M)(61.92M)(86.97M)
Net Margin————
EPS (Basic)(0.82)(1.02)(1.85)(2.38)
EPS (Diluted)(0.82)(1.02)(1.85)(2.38)
Weighted Avg Shares31.85M31.85M33.39M36.51M
Weighted Avg Shares (Diluted)31.85M31.85M33.39M36.51M

MBX Biosciences, Inc. Common Stock

NASDAQ:MBX

Intrinsic Alpha fair value

Locked

Current Price

$53.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.